Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC

Personalised systemic treatment in advanced prostate cancer

World Bladder Cancer Patient Coalition

DNA methylation profile of prostate cancer aggressiveness in Ghana

ESMO 2023: Highlights and analysis

Adjuvant radiotherapy has no benefit following radical prostatectomy

Where do we stand with mCRPC?

PARPi combinations to treat patients with mCRPC